MANGOCEUTICALS, INC. Files 8-K Report

Ticker: MGRX · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1938046

Mangoceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyMangoceuticals, INC. (MGRX)
Form Type8-K
Filed DateOct 21, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

MANGOCEUTICALS, INC. filed an 8-K. Check for updates on financials/exhibits.

AI Summary

On October 21, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates MANGOCEUTICALS, INC. is providing updates or disclosures required by the SEC, potentially related to financial statements or other material information.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing cover page and does not contain specific operational or financial details that would indicate a high risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for MANGOCEUTICALS, INC.?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was this 8-K report filed?

The report was filed on October 21, 2024.

In which state is MANGOCEUTICALS, INC. incorporated?

MANGOCEUTICALS, INC. is incorporated in Texas.

What is the principal executive office address for MANGOCEUTICALS, INC.?

The principal executive office is located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.

What is the Commission File Number for MANGOCEUTICALS, INC.?

The Commission File Number is 001-41615.

Filing Stats: 876 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-10-21 17:10:26

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: October 21, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing